Mycobacterium Avium-Intracellulare Infection Clinical Trial
Official title:
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterial in Previously Treated or Moderate to Severe Pulmonary Mycobacterium Avium Complex (MAC) Infection
This study will test the safety and effectiveness of inhaled interferon gamma-1b and oral
antibiotics for treating mycobacterium avium complex (MAC) infection of the lungs.
Patients 18 years of age or older with MAC infection of the lungs who 1) have been
previously treated for MAC, or 2) have moderate or severe lung disease due to MAC that has
not been previously treated may be eligible for this study.
Participants will be randomly assigned to one of two treatment groups. Group 1 will receive
500 micrograms of interferon gamma-1b 3 times a week for 48 weeks by inhalation. Group 2
will inhale a placebo (inactive substance) according to the same regimen. In addition, all
patients will receive standard MAC treatment with three antibiotics-clarithromycin or
azithromycin, ethambutol and rifampin or rifabutin-taken by mouth times a week.
Patients will come to the clinic for a screening visit, baseline visit, 1 month after
beginning treatment, and at 3-month intervals thereafter until the end of the study. During
these various visits, they will undergo the following tests and procedures:
- Medical history and physical examination, including height and weight measurements,
heart rate, breathing rate, blood pressure and temperature
- Possibly computed tomography (CT) and X-ray of the lungs
- Sputum sample
- Pulmonary function studies
- Blood and urine tests
Patients' eyes will be examined monthly to check for side effects of ethambutol, and hearing
and balance will be tested to check for side effects of clarithromycin or azithromycin.
At the baseline visit, the patient or caretaker will be trained to use a nebulizer (a
special breathing device) to take the study medication.
Nontuberculous mycobacterial infections due to Mycobacterium avium complex (MAC) are a growing problem among older Americans, especially women. These organisms are relatively resistant to antituberculous medications and frequently persist or recur. In patients with disseminated infections, interferon gamma has been shown to be a critical cytokine in the resistance to and therapy of these infections. Previous experience with injected interferon gamma has been relatively disappointing, with clinical response rates in conventional therapy-refractory patients of about 20%. Aerosol administration of interferon gamma has been shown to rapidly convert sputum smears to negative in multidrug resistant tuberculosis and in one case of MAC infection. However, in these short-term experiments, cultures have remained positive and patients have had clinical relapse. In addition, aerosol administration of interferon gamma has significantly less systemic activation and side effects than does systemic administration. Therefore, we propose to administer interferon gamma by aerosol into the lungs of patients with MAC infection that has persisted despite adequate conventional therapy. This aerosol will be delivered 3 times weekly by the patient. This trial is randomized and double blinded. The period of therapy is 48 weeks and the follow up is another 48 weeks. All patients must be on conventional therapy at the same time and have organisms that are macrolide sensitive. Screening and treatment will be conducted at the NIH Clinical Center as well as multiple collaborative sites. This study should clarify the therapeutic role for aerosolized interferon gamma in the treatment of nontuberculous mycobacterial infections. ;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00000883 -
Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy
|
N/A | |
Completed |
NCT00111397 -
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
|
Phase 1 | |
Completed |
NCT00004689 -
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
|
Phase 2 | |
Completed |
NCT00001763 -
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection
|
Phase 1 | |
Recruiting |
NCT05824988 -
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
|
||
Completed |
NCT00002104 -
Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV
|
Phase 1 | |
Completed |
NCT00002140 -
A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients
|
Phase 3 | |
Completed |
NCT00001039 -
Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
|
Phase 2 | |
Completed |
NCT00000641 -
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
|
Phase 2 | |
Completed |
NCT00002089 -
An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy
|
N/A | |
Completed |
NCT00000947 -
A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients
|
N/A | |
Completed |
NCT00002080 -
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
|
N/A | |
Completed |
NCT00002090 -
An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)
|
N/A | |
Completed |
NCT00000860 -
The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients
|
N/A | |
Completed |
NCT00002058 -
A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease
|
N/A | |
Completed |
NCT00002170 -
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
|
Phase 2 | |
Completed |
NCT00000907 -
A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
|
N/A | |
Completed |
NCT00002037 -
Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study
|
N/A | |
Completed |
NCT00000895 -
A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
|
N/A | |
Completed |
NCT00002085 -
A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy
|
N/A |